Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment
Authors
Carole Rubino
Akthar Shamsaldin
Monique G. Lê
Martine Labbé
Jean-Marc Guinebretière
Jean Chavaudra
Florent de Vathaire
Publication date
01-02-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-004-2472-8

Other articles of this Issue 3/2005

Breast Cancer Research and Treatment 3/2005 Go to the issue

Report

Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer

OriginalPaper

Racial differences in the familial aggregation of breast cancer and other female cancers

Brief communication

Improvement in intramammary sentinel lymph node removal using a novel prototype hand held probe during breast conservative surgery

Brief Communication

Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression

Erratum

Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells

Letter to the editor

Possible role of CXCR4-mediated chemotaxis in breast cancer patients with central nervous system metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits